Anticoagulants, Antiplatelets, and Thrombolytics
Springer Science & Business Media, 2004 - 307
During the past decade, remarkable progress has been made in the development of new drugs to treat thrombotic and cardiovascular diseases, the number one cause of mortality worldwide. In Anticoagulants, Antiplatelets, and Thrombolytics, leading experts with established records of discovery and invention highlight the latest developments in antithrombotics and provide experimental methods for the discovery of new and improved anticoagulants. Among the cutting-edge developments reviewed are the novel usage of low molecular weight heparins, such antithrombin agents as hirudin, and such antiplatelet drugs as the GPIIb/IIIa inhibitors and ADP-receptor antagonists. Additional innovations discussed include aspirin and clopidogrel, the expanded use of polytherapeutic approaches, antiproteases (factors IIa, Xa, and VIIa), tissue-factor targeting, platelet-receptor targeting, and antithrombin III modulation. The authors also define the clinically relevant in vitro and in vivo models of thrombosis and hemostasis that led to these advances and that will surely aid in the discovery of the next generation of antithrombotics. Up-to-date and forward-looking, Anticoagulants, Antiplatelets, and Thrombolytics illuminates the latest developments in the field of thrombosis and provides both basic and clinical investigators a broad array of successful experimental methods for the discovery and development of novel drugs to treat thrombotic and cardiovascular diseases.
Co mówią ludzie - Napisz recenzję
Nie znaleziono żadnych recenzji w standardowych lokalizacjach.
Highlights of Latest Advances in Antithrombotics
Antiplatelet Anticoagulant and Thrombolytic Drug Interactions
Evaluation of Platelet Antagonists in In Vitro Flow Models
Heparin and Low Molecular Weight Heparin in Thrombosis
Are Low Molecular Weight Heparins the Same?
Antithrombotic Drugs for the Treatment of HeparinInduced
Laboratory Methods for HeparinInduced Thrombocytopenia
Factor Xa Inhibitors
Tissue Factor Pathway Inhibitor in Thrombosis and Beyond
A Survey of Venous Thrombosis Models
Oral Thrombin Inhibitor Ximelagatran
Guidelines for Diagnosis and Treatment of Deep Venous
Tissue FactorVIIa in Thrombosis and Cancer
abciximab adhesion animal models antibody anticoagulant antiplatelet antithrombotic antithrombotic agents antithrombotic effect aPTT argatroban Arixtra arterial thrombosis aspirin assay atherosclerotic binding bioavailability bleeding blood cancer Circulation Clin clinical trials clot coagulation factor coronary artery deep vein thrombosis demonstrated direct thrombin inhibitor disease dose drugs efficacy endothelial cells enoxaparin evaluation factor pathway inhibitor factor Xa factor Xa inhibitors flow fondaparinux gene GPIIb/IIIa GPIIb/IIIa antagonists Haemostasis heparin heparin-induced thrombocytopenia hirudin human induced inhibition integrin interactions LMWHs low molecular weight models of thrombosis molecular weight heparin Mousa myocardial infarction oral patients with HIT pentasaccharide pharmacokinetic pharmacological plasma plasminogen platelet activation platelet aggregation potential protein rabbit receptor recombinant renal risk role studies Suppl surgery synthetic TFPI therapeutic therapy Thromb thrombogenic thrombolytic thrombosis model thrombotic thrombus formation tinzaparin tion tissue factor tissue factor pathway treatment vascular venous thromboembolism venous thrombosis vessel vitro vivo Walenga warfarin ximelagatran